Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmaco-Neuroimaging Study of BTRX-246040 in MDD and Anxiety Disorders
NCT05232032Phase 2Recruiting
- Sponsor
- McLean Hospital
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY2940094 in major depressive disorder (MDD), anxiety disorder, sponsored by McLean Hospital. Started Feb 2025; status: recruiting.
02
Drugs
LY2940094
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT05232032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232032.